ILLUMINA INC
ILMNNASDAQTrading Snapshot
- Day Range
- $267.45 – $274.98
- 52-Week Range
- $88.00 – $277.95
- Volume
- $5.75B
- Avg Volume
- $6.95B
- Shares Outstanding
- 151.3M
- Next Earnings
- Nov 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $4.34B
- Last Q Revenue
- $1.16B
- P/E Ratio
- 49.9
- P/S Ratio
- 9.1x
- EPS (TTM)
- $5.46
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −3.7%
Why Investors Own ILMN
- ✓High-growth profile — revenue up +8.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 41% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ILLUMINA INC
ILMN
StockOtter · stockotter.spaceAbout ILLUMINA INC
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
REGN or ILMN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Is the Options Market Predicting a Spike in Illumina Stock?
Investors need to pay close attention to ILMN stock based on the movements in the options market lately.
Illumina (NASDAQ:ILMN) Reaches New 52-Week High – Here’s Why
Illumina, Inc. (NASDAQ: ILMN - Get Free Report) shares reached a new 52-week high during mid-day trading on Wednesday. The company traded as high as $254.85 and last traded at $252.2590, with a volume of 189250 shares ch
Illumina Stock Surges 94.9% YTD: What's Behind the Rally?
ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.
3 Analysts, 3 Trades to Make Today
Louis says buy the AI dip
Illumina (ILMN) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.